-
AbbVie’s Allergan Aesthetics Secures NMPA Approval for Juvéderm VOLUMA with Lidocaine
•
Allergan Aesthetics, a subsidiary of AbbVie (NYSE: ABBV), has announced that it has received marketing approval from the National Medical Products Administration (NMPA) for Juvéderm VOLUMA with Lidocaine, expanding its indications to include nose augmentation procedures. Product Description and BenefitsJuvéderm VOLUMA with Lidocaine is a cross-linked sodium hyaluronate gel designed…
-
Northeast Pharmaceutical Partners with Muscat Changming for Middle East Expansion
•
China-based Northeast Pharmaceutical Co., Ltd (SHE: 000597) has entered into an investment framework agreement with Muscat Changming Investments LLC, leveraging business development plans and market demand in Oman and the Middle East. Joint Venture Establishment and ObjectivesThe partnership aims to establish a joint venture (JV) in the Sultanate of Oman,…
-
Caliway Biopharmaceuticals’ CBL-514 Achieves Milestones in Dercum’s Disease Trial
•
Taiwan-based Caliway Biopharmaceuticals, a specialist in medical aesthetics and inflammatory medicine, has announced that its trial assessing the efficacy and safety of CBL-514 in subjects with Dercum’s Disease lipomas has met all primary and secondary efficacy endpoints. CBL-514 is a first-in-class small-molecule injection lipolysis drug designed to induce adipocyte apoptosis…
-
BRIM Biotechnology Raises $45.8 Million in Premium Share Issue for Pipeline Expansion
•
Taiwan-based BRIM Biotechnology, Inc. (TPEx 6885), a biotechnology company specializing in the development of regenerative peptides for ophthalmology and degenerative joint diseases, has announced the successful issuance of 22,500 shares at a premium of USD 2.03, raising a total of USD 45.8 million. The rights issue was fully paid on…
-
Suzhou Acumen Biomedical Secures $13.8 Million in Series A+ Funding Round
•
China’s Suzhou Acumen Biomedical Technology Co., Ltd. has reportedly raised close to RMB 100 million (USD 13.8 million) in a Series A+ financing round. The round was led by Qiandao Investment Fund, with participation from Broad Resource Investment. The funds raised will be allocated towards the expansion of the company’s…
-
MicroPort MedBot’s SkyWalker Robot Approved for Orthopedic Surgery by NMPA
•
Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) has announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its innovative navigation and positioning system, the SkyWalker hip and knee joint replacement surgery robot. This marks the first approval of an in-house developed mechanical arm…
-
Zhejiang Medicine Gets NMPA Approval for NCB003 Clinical Study for Advanced Solid Tumors
•
Zhejiang Medicine Co., Ltd (SHA: 600216), a China-based pharmaceutical company, has announced that it has received approval from the National Medical Products Administration (NMPA) to initiate a clinical study for its investigational injectable drug, NCB003. This next-generation targeted coupling long-acting human interleukin-2 (IL-2) drug is being developed to treat patients…
